Wealth Enhancement Advisory Services LLC Has $297,000 Stock Position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)

Wealth Enhancement Advisory Services LLC reduced its stake in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE - Free Report) by 67.6% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 7,052 shares of the biopharmaceutical company's stock after selling 14,701 shares during the quarter. Wealth Enhancement Advisory Services LLC's holdings in Ultragenyx Pharmaceutical were worth $297,000 as of its most recent SEC filing.

Several other hedge funds have also recently bought and sold shares of the stock. Universal Beteiligungs und Servicegesellschaft mbH acquired a new stake in shares of Ultragenyx Pharmaceutical during the fourth quarter worth approximately $5,505,000. Mackenzie Financial Corp increased its holdings in shares of Ultragenyx Pharmaceutical by 275.6% during the fourth quarter. Mackenzie Financial Corp now owns 16,115 shares of the biopharmaceutical company's stock worth $678,000 after buying an additional 11,825 shares in the last quarter. GF Fund Management CO. LTD. acquired a new stake in shares of Ultragenyx Pharmaceutical during the fourth quarter worth approximately $82,000. Frazier Life Sciences Management L.P. increased its holdings in shares of Ultragenyx Pharmaceutical by 3.9% during the fourth quarter. Frazier Life Sciences Management L.P. now owns 658,715 shares of the biopharmaceutical company's stock worth $27,712,000 after buying an additional 25,000 shares in the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its holdings in shares of Ultragenyx Pharmaceutical by 13.9% during the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 202,376 shares of the biopharmaceutical company's stock worth $8,514,000 after buying an additional 24,620 shares in the last quarter. 97.67% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research analysts have issued reports on RARE shares. Morgan Stanley upped their price objective on Ultragenyx Pharmaceutical from $64.00 to $65.00 and gave the stock an "overweight" rating in a report on Friday, May 9th. Canaccord Genuity Group upped their price objective on Ultragenyx Pharmaceutical from $121.00 to $136.00 and gave the stock a "buy" rating in a report on Tuesday, February 18th. William Blair began coverage on Ultragenyx Pharmaceutical in a report on Wednesday, May 28th. They issued an "outperform" rating and a $65.00 price target on the stock. JPMorgan Chase & Co. raised their price target on Ultragenyx Pharmaceutical from $104.00 to $117.00 and gave the company an "overweight" rating in a report on Thursday, March 27th. Finally, Cantor Fitzgerald reiterated an "overweight" rating and issued a $118.00 price target on shares of Ultragenyx Pharmaceutical in a report on Wednesday, February 26th. One research analyst has rated the stock with a hold rating and twelve have issued a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $88.77.

Ultragenyx Pharmaceutical Stock Performance

RARE traded down $0.39 during trading on Monday, reaching $37.10. 78,819 shares of the company's stock were exchanged, compared to its average volume of 838,721. The company's fifty day moving average price is $36.04 and its 200-day moving average price is $39.97. Ultragenyx Pharmaceutical Inc. has a fifty-two week low of $29.59 and a fifty-two week high of $60.37. The firm has a market capitalization of $3.51 billion, a PE ratio of -5.87 and a beta of 0.25.

Ultragenyx Pharmaceutical (NASDAQ:RARE - Get Free Report) last released its earnings results on Tuesday, May 6th. The biopharmaceutical company reported ($1.57) EPS for the quarter, missing analysts' consensus estimates of ($1.54) by ($0.03). Ultragenyx Pharmaceutical had a negative return on equity of 193.80% and a negative net margin of 101.60%. The business had revenue of $139.29 million for the quarter, compared to analyst estimates of $145.98 million. During the same period in the prior year, the firm posted ($2.03) EPS. Ultragenyx Pharmaceutical's revenue was up 28.0% on a year-over-year basis. Research analysts forecast that Ultragenyx Pharmaceutical Inc. will post -5.18 earnings per share for the current fiscal year.

Ultragenyx Pharmaceutical Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.